Evaluation of BL-P1654: a semisynthetic penicillin as a topical ocular therapy.
BL-P1654 is a new semisynthetic penicillin that possesses broad spectrum antimicrobial activity against many gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa. An in vitro profile of BL-P1654 was established against strains of Staphylococcus aureus, Streptococcus pneumoniae, and Pseudomonas aeruginosa, three bacteria frequently associated with infections of the eye. The effectiveness of BL-P1654 in preventing the development of experimentally-induced keratitis by each of these bacteria was determined. The results of these experiments show BL-P1654 to be more effective than gentamicin and support further evaluation of the semisynthetic penicillin for ophthalmic indications.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical; D005260:Female; D005839:Gentamicins / Q000494:pharmacology / Q000627:therapeutic use; D007634:Keratitis / Q000517:prevention & control*; D008297:Male; D010397:Penicillanic Acid / Q000494:pharmacology / Q000627:therapeutic use* / Q000031:analogs & derivatives; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011817:Rabbits; D013211:Staphylococcus aureus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects
D000900:Anti-Bacterial Agents; D005839:Gentamicins; C009705:BLP 1654; D010397:Penicillanic Acid